Citius Pharmaceuticals Inc (CTXR)

[conix]

Citius Pharmaceuticals Inc (NASDAQ:CTXR) CEO Myron Z. Holubiak Acquires 558,597 Shares

Posted by Joseph Griffin on Sep 30th, 2019


Citius Pharmaceuticals logoCitius Pharmaceuticals Inc (NASDAQ:CTXR) CEO Myron Z. Holubiak bought 558,597 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $0.90 per share, for a total transaction of $502,737.30.

Shares of NASDAQ CTXR traded up $0.01 during mid-day trading on Monday, reaching $0.73. 200 shares of the company’s stock were exchanged, compared to its average volume of 193,781. The firm has a market capitalization of $16.45 million, a price-to-earnings ratio of -0.62 and a beta of 0.67. Citius Pharmaceuticals Inc has a 52 week low of $0.67 and a 52 week high of $2.52. The firm has a 50-day moving average price of $1.04 and a two-hundred day moving average price of $1.14.


A number of equities research analysts have recently commented on CTXR shares. Zacks Investment Research cut Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 23rd. Dawson James started coverage on Citius Pharmaceuticals in a research note on Friday, September 6th. They set a “buy” rating and a $7.00 target price on the stock.


A hedge fund recently raised its stake in Citius Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 453,156 shares of the company’s stock after purchasing an additional 342,180 shares during the period. Vanguard Group Inc. owned about 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent reporting period. Institutional investors own 2.83% of the company’s stock.
About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.